Osteoclasts: The Bone-Resorbing Cells That Drive Osteoporosis When Overactive
Osteoclasts are large, multinucleated cells that dissolve and resorb bone tissue as part of the normal remodeling cycle — overactivity causes osteoporosis.
Osteoclasts are large, multinucleated cells responsible for resorbing (breaking down) bone tissue. They dissolve the mineral component with hydrochloric acid and digest the collagen matrix with enzymes, releasing calcium and phosphorus into the bloodstream. This process is part of the continuous bone remodeling cycle that renews the skeleton throughout life. In healthy bone, osteoclast activity is balanced by Osteoblasts: The Bone-Building Cells That Strengthen Your Skeleton activity (bone formation). When osteoclasts become overactive relative to osteoblasts — due to estrogen decline after menopause, aging, or certain medications — the result is net bone loss: Osteoporosis: When Bone Breakdown Outpaces Bone Building. ## Therapeutic Targets Most osteoporosis drugs work by inhibiting osteoclasts: - **Bisphosphonates: The First-Line Defense Against Osteoporosis** (alendronate, risedronate): Bind to bone mineral and trigger osteoclast apoptosis - **Denosumab: The Antibody That Stops Bone-Eating Cells but Can't Be Stopped Easily**: Blocks RANKL signaling, preventing osteoclast formation entirely Osteoclasts form from monocyte/macrophage precursors under the influence of two key signals: M-CSF (macrophage colony-stimulating factor) and RANKL. Both represent potential therapeutic targets.